Background
Significant investments to combat the HIV epidemic in sub-Saharan Africa (SSA), have resulted in progress towards new HIV-1 prevention options; however, the epidemic continues to disproportionally affect adolescent girls and young women (AGYW) [Advances in biomedical HIV prevention will soon offer young women a choice of multiple female-controlled HIV prevention methods, including oral antiretroviral pre-exposure prophylaxis (PrEP), the dapivirine vaginal ring, and long-acting injectable cabotegravir [The UChoose Study was designed to evaluate the acceptability and preference for several contraceptive options as a proxy for HIV prevention methods with similar routes of administration [By understanding preferences for contraceptive methods, we may draw analogies for the HIV prevention needs of young women [